CORONA, statins, and heart failure: Who lost the crown?

Angiology

Volumn 59, Issue 1, 2008, Pages 5-8

  Athyros, Vasilios G ^a   Kakafika, Anna I ^a   Tziomalos, Konstantinos ^a,b   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROHORMONE; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADRENERGIC SYSTEM; AGED; AORTA ELASTICITY; ATTENUATION; AUTONOMIC NERVOUS SYSTEM; CLINICAL STUDY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED ROSUVASTATIN MULTINATIONAL TRIAL IN HEART FAILURE; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; ELASTICITY; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART RATE VARIABILITY; HIGH RISK PATIENT; HORMONE ACTION; HOSPITALIZATION; HUMAN; INFLAMMATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MODULATION; MORBIDITY; MORTALITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; RISK REDUCTION;

EID: 39149089954     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319707313882     Document Type: Editorial

References (30)

1. Tsouli SG, Liberopoulos EN, Goudevenos JA, et al. Should a statin be prescribed to every patient with heart failure? [published online ahead of print August 12, 2007]. Heart Fail Rev. PMID:17694432.
2. Shanes JG, Minadeo KN, Moret A., et al. Statin therapy in heart failure: prognostic effects and potential mechanisms. Am Heart J. 2007 ; 154: 617-623.
3. Tousoulis D., Charakida M., Stefanadi E., et al. Statins in heart failure. Beyond the lipid-lowering effect. Int J Cardiol. 2007 ; 115: 144-150.
4. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007 ; 357: 2248-2261.
5. Go AS, Lee WY, Yang J., et al. Statin therapy and risks for death and hospitalization in chronic heart failure JAMA. 2006 ; 296: 2105-2111.
6. Foody JM, Shah R., Galusha D., et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation. 2006 ; 113: 1086-1092.
7. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators: intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 ; 352: 1425-1435.
8. Khush KK, Waters DD, Bittner V., et al. Effect of high-dose atorvastatin on hospitalizations for heart failure. Subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007 ; 115: 576-583.
9. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus "usual" care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study Curr Med Res Opin. 2002 ; 18: 220-228.
10. FDA. Lipitor®. (Atorvastatin Calcium) Tablets. http://www.fda.gov/ medwatch/safety/2007/Sep_PI/Lipitor_PI.pdf. Accessed December 29, 2007.
11. Kjekshus J., Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997 ; 3: 249-254.
12. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004 ; 292: 1307-1316.
13. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998 ; 339: 1349-1357.
14. Sola S., Mir MQ, Lerakis S., et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006 ; 47: 332-337.
15. van der Harst P., Voors AA, van Gilst WH Statins and autonomic function in chronic heart failure. Cardiovasc Drugs Ther. 2005 ; 19: 167-168.
16. Bonaduce D., Petretta M., Marciano F., et al. Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure Am Heart J. 1999 ; 138: 273-284.
17. Pehlivanidis AN, Athyros VG, Demitriadis DS, et al. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease Atherosclerosis. 2001 ; 157: 463-469.
18. Hanna IR, Heeke B., Bush H., et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm. 2006 ; 3: 881-886.
19. Ganotakis ES, Mikhailidis DP, Vardas PE Atrial fibrillation, inflammation, and statins. Hellenic J Cardiol. 2006 ; 47: 51-53.
20. Tziomalos K., Athyros VG, Karagiannis A., et al. Endothelial function, arterial stiffness, and lipid-lowering drugs. Expert Opin Ther Targets. 2007 ; 11: 1143-1160.
21. Kontopoulos AG, Athyros VG, Pehlivanidis AN, et al. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Curr Med Res Opin. 2003 ; 19: 22-27.
22. Hillege HL, Nitsch D., Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006 ; 113: 671-678.
23. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. J Clin Pathol. 2004 ; 57: 728-734.
24. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant. 2007 ; 22: 118-127.
25. Tonelli M., Moyé L., Sacks FM, et al. Cholesterol and Recurrent Events Trial Investigators: effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003 ; 14: 1605-1613.
26. Collins R., Armitage J., Parish S., et al. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial Lancet. 2003 ; 361: 2005-2016.
27. Youssef F., Gupta P., Seifalian AM, et al. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology. 2004 ; 55: 53-62.
28. Shepherd J., Kastelein JJ, Bittner V., et al. Treating to New Targets Investigators: effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007 ; 2: 1131-1139.
29. Liberopoulos EN, Mikhailidis DP, Athyros VG, et al. The effect of cholesterol-lowering treatment on renal function. Am J Kidney Dis. 2006 ; 47: 561.
30. Tavazzi L., Tognoni G., Franzosi MG, et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004 ; 6: 635-641.